A state-based model for management of type II diabetes

Studies in Computational Intelligence

Volumn 48, Issue , 2007, Pages 27-61

  Sordo, Margarita ^a   Hongsermeier, Tonya ^b   Kashyap, Vipul ^b   Greenes, Robert A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b PARTNERS HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34247859283     PISSN: 1860949X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-47527-9_2     Document Type: Article

References (35)

1. National Center for Chronic Disease Prevention and Health Promotion. National Diabetes Surveillance System. http://www.cdc.gov/diabetes/ statistics/prev/national/index.htm
2. Appel GB. Improved outcomes in nephrotic syndrome. Cleve Clin J Med. 2006; 73(2):161-167. Review
3. Diabetes Disparities among Racial and Ethnic Minorities. Agency for Healthcare Research and Quality Fact Sheet. Accessed at http://www.ahrq.gov/research/diabdisp.htm
4. Snow V, Aronson MD, Hornbake ER, Mottur-Pilson C, Weiss KB. Lipid control in the management of type 2 diabetes mellitus: A clinical practice guideline from the American College of Physicians. Ann Intern Med. 2004; 140(8):644-649
5. Vijan S, Hayward RA. Treatment of hypertension in type 2 diabetes mellitus: Blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med. 2003; 138:593-602
6. Vijan S, Hayward RA. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: Background paper for the American College of Physicians. Ann Intern Med. 2004; 140:650-658
7. Clinical Informatics Research and Development (CIRD). Partners Healthcare. http://www.partners.org/cird/AboutUs.asp
8. American Diabetes Association. Consensus development conference on the diagnosis of coronary heart disease in people with diabetes (Consensus Statement). Dia Care. 1998; 21:1551-1559
9. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, Camel G, Davis BR, Frost PH, Gonzalez N, Guthrie G, Oberman A, Rutan GH, Stamler J. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic hypertension in the Elderly Program Cooperative Research Group. JAMA. 1996; 276(23):1886-1892. Erratum in: JAMA 1997; 277(17):1356
10. Fuller J, Stevens LK, Chaturvedi N, Holloway JF. Antihypertensive therapy for preventing cardiovascular complications in people with diabetes mellitus. Cochrane Database Syst Rev. 2000; (2):CD002188
11. Staessen JA, Thijisq L, Fagard R, Celis H, Birkenhager WH, Bulpitt CJ, de Leeuw PW, Fletcher AE, Forette F, Leonetti G, McCormack P, Nachev C, O'Brien E, Rodicio JL, Rosenfeld J, Sarti C, Tuomilehto J, Webster J, Yodfat Y, Zanchetti A. Systolic hypertension in Europe (Syst-Eur) trial investigators. Effects of immediate versus delayed antihypertensive therapy on outcome in the systolic hypertension in Europe trial. J Hypertens. 2004; 22(4):847-857
12. Hayden M, Pignone, M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: A summary of the evidence for the U.S. preventive services task force. Ann Intern Med. 2002; 136:161-172
13. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. Irbesartan in patients with type 2 diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001; 345(12):870-878
14. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998; 317:713-720
15. US Preventive Services Task Force: Aspirin for the primary prevention of cardiovascular events: Recommendation and rationale. Ann Intern Med. 2002; 136: 157-160
16. Barret-Connor E, Khaw K-T. Cigarette smoking and increased central adiposity. Ann Intern Med. 1989; 111:783-787
17. Facchini FS, Hollenbeck CB, Jeppesen J, Chen YD, Reaven GM. Insulin resistance and cigarette smoking. Lancet. 1992; 339:1128-1130
18. Kawakami N, Takatsuka N, Shimizu H, Ishibashi H. Effects of smoking on the incidence of non-insulin-dependent diabetes mellitus. Am J Epidemiol. 1997; 145:103-109
19. Rimm EB, Chan J, Stampfer MJ, Colditz GA, Willett WC. Prospective study of cigarette smoking, alcohol use, and the risk of diabetes in men. BMJ 1995; 310:555-559
20. Bazzano LA, He J, Muntner P, Vupputuri S,Whelton PK. Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann Intern Med. 2003; 138(11):891-897
21. Leiter LA, Fitchett D. Optimal care of cardiovascular disease and type 2 diabetes patients: Shared responsibilities between the cardiologist and diabetologist. Atheroscler Suppl. 2006; 7(1):37-42
22. American Diabetes Association. Standards of medical care in diabetes. Dia Care. 2004; 27(Suppl. 1): S15-S35
23. Smith SA, Poland GA: The use of influenza and pneumococcal vaccines in people with diabetes (Technical Review). Dia Care. 2000; 23:95-108
24. Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices (ACIP): Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP). http://www.cdc.gov/
25. Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrott M. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem. 2002; 48(3):436-472
26. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42(6):1206-1252
27. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998; 351(9118):1755-1762
28. Gall MA, Hougaard P, Borch-Johnsen K, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: Prospective, observational study. BMJ. 1997; 314(7083):783-788
29. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDSG 33). Lancet. 1998; 352:837-853
30. Shoda J, Kanno Y, Suzuki H. A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy. Intern Med. 2006; 45(4):193-198
31. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, et al. Preserving renal function in adults with hypertension and diabetes: A consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000; 36:646-661
32. Herman WH, Shahinfar S, Carides GW, Dasbach EJ, Gerth WC, Alexander CM, Cook JR, Keane WF, Brenner BM. Lozartan reduces the costs associated with diabetic end-stage renal disease: The RENAAL study economic evaluation. Dia Care. 2003; 26(3):683-687
33. Object Management Group - UML. http://www.uml.org/
34. Douglass BP. UML Statecharts. http://www-md.e-technik.uni-rostock.de/ma/ gol/ilogix/umlsct.pdf
35. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998; 317(7160):703-713